中继治疗报告,其实验药物RLY-2608在治疗难治疗的乳腺癌、显示肿瘤萎缩和良好的安全状况方面,有望取得早期结果。 Relay Therapeutics reports promising early results for its experimental drug RLY-2608 in treating hard-to-treat breast cancers, showing tumor shrinkage and a good safety profile.

中继治疗报告,在其实验药物RLY-2608的试验中,在治疗难治疗的乳腺癌,包括三联阴性和荷尔蒙受体阳性类型方面,早期取得了积极结果。 Relay Therapeutics reports early positive results from a trial of its experimental drug RLY-2608 in treating difficult-to-treat breast cancers, including triple-negative and hormone receptor-positive types. 该药物针对与癌症生长有关的蛋白质,导致一些病人的肿瘤严重萎缩,并观察到部分或完整反应。 The drug, which targets a protein linked to cancer growth, caused significant tumor shrinkage in some patients, with partial or complete responses observed. 调查结果强调RLY-2608作为已用尽标准疗法的病人的新治疗方案的潜力, Presented at a medical conference, the findings highlight RLY-2608’s potential as a new treatment option for patients who have exhausted standard therapies, along with a favorable safety profile in early testing. 虽然数据仍处于早期开发阶段,但已引发了乐观情绪,促使中继将药物推向更大的试验。 While still in early development, the data have sparked optimism, prompting Relay to advance the drug into larger trials. 需要进行进一步的研究,以确认长期的有效性和安全性。 Further research is needed to confirm long-term effectiveness and safety.